Canaccord Genuity Downgrades Endologix (ELGX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Leerink Partners Cuts Price Target on Endologix (ELGX) to $8 Following Analyst Day
November 18, 2016 7:20 AM ESTLeerink Partners maintained a Market Perform rating on Endologix (NASDAQ: ELGX), and cut the price target to $8.00 (from $11.00), following the company's analyst day. The focus of the presentation was around Nellix. There was news on Wednesday that potential approval has been pushed out ~6 months. This comes following a request for additional info from the FDA. Management also updated 2016 revenue... More
Endologix (ELGX) trading halted with news pending
November 16, 2016 8:55 AM ESTEndologix (NASDAQ: ELGX) trading halted with news pending.
... More